BioCryst wins US Ebola contract potentially worth $35m
This article was originally published in Scrip
Executive Summary
The US Biomedical Advanced Research and Development Authority (BARDA) has awarded BioCryst Pharmaceuticals $12m to advance the development of its experimental Ebola drug BCX4430 – a contract that could ultimately be worth $35m.